CureVac GmbH

100 articles with CureVac GmbH

• CureVac's COVID-19 Vaccine Candidate, CVnCoV, Demonstrated Efficient Protection of Non-Human Primates During SARS-CoV-2 Challenge Infection

  1/11/2021

  Data provided further evidence on immunogenicity and protective efficacy of CVnCoV Induction of robust antibody and T cell responses at lower dose than tested in Phase 3 trial Full lung protection of CVnCoV-vaccinated animals during SARS-CoV-2 challenge infection

• 

  Biopharma Companies Entering 2021 With New Collabs, Partnerships

  1/8/2021

  Here’s a run-down of some of the most recent collaboration announcements this week.
• 

  Biopharma Update on the Novel Coronavirus: December 22

  12/22/2020

  Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for December 22, 2020.

• CureVac and the University Medical Center Mainz Start Phase 3 Clinical Trial for COVID-19 Vaccine Candidate, CVnCoV, in Healthcare Workers

  12/21/2020

  CureVac N.V., a global clinical-stage biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid, announced that the first participant in a clinical Phase 3 study with its COVID-19 vaccine, CVnCoV, in healthcare workers at the University Medical Center Mainz will be vaccinated on December 22, 2020.

• 

  Clinical Catch-Up: December 14-18

  12/21/2020

  Many companies appear to be getting their clinical trial news updated ahead of the holidays. Here’s a look.
• 

  Biopharma Update on the Novel Coronavirus: December 15

  12/15/2020

  Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for December 15, 2020.

• CureVac : CureVac Commences Global Pivotal Phase 2b/3 Trial for COVID-19 Vaccine Candidate, CVnCoV

  12/14/2020

  First individual enrolled in Phase 2b/3 study to assess efficacy and safety of CVnCoV. Study expected to enroll more than 35,000 participants, focusing on Europe and Latin America

• 

  CureVac Begins Phase IIb/III Trial of Its mRNA COVID-19 Vaccine

  12/14/2020

  Germany’s CureVac announced it has enrolled the first volunteer in the pivotal Phase IIb/III trial of its own mRNA vaccine candidate, CVnCoV against COVID-19.

• CureVac Appoints Antony Blanc as Chief Business Officer and Chief Commercial Officer

  12/4/2020

  CureVac N.V. (NASDAQ:CVAC), a global clinical-stage biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid announced today that Antony Blanc, PhD, was appointed Chief Business Officer and Chief Commercial Officer of CureVac.

• CureVac to Report Third Quarter and First Nine Months 2020 Financial Results and Business Updates on November 30, 2020

  11/26/2020

  CureVac N.V., a biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid, will report financial results and business updates for the third quarter and first nine months of 2020 on Monday, November 30, 2020.

• CureVac Establishes European-Based Network to Ramp Up Manufacturing of its COVID-19 Vaccine Candidate, CVnCoV

  11/17/2020

  CureVac N.V., a biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid, announced that it is accelerating the expansion of its manufacturing network to deliver pandemic-scale volumes of its COVID-19 vaccine candidate, CVnCoV.

• European Commission Announces That Tomorrow It Will Authorize the Agreement with CureVac for the Supply of up to 405 Million Doses of mRNA-Based COVID-19 Vaccine Candidate, CVnCoV

  11/16/2020

  CureVac N.V., a biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid, reports the European Commission's announcement that tomorrow it will authorize an Advanced Purchase Agreement for CureVac's mRNA-based COVID-19 vaccine candidate, CVnCoV.

• CureVac Publishes Detailed Interim Phase 1 Data of its COVID-19 Vaccine Candidate, CVnCoV

  11/10/2020

  CureVac N.V., a clinical-stage biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid, announced publication of detailed interim Phase 1 data, following the reporting of positive topline data on November 2, 2020.

• 

  Biopharma Update on the Novel Coronavirus: November 10

  11/10/2020

  Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for November 10, 2020.
• 

  Biopharma Update on the Novel Coronavirus: November 3

  11/3/2020

  Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for November 3, 2020.
• 

  Study: CureVac’s COVID-19 Vaccine Produces Immune Responses in Healthy Volunteers

  11/2/2020

  Newly announced results of a Phase I dose-escalation study show CureVac’s COVID-19 vaccine candidate, CVnCoV, generates noticeable immune responses in healthy volunteers.

• CureVac: CureVac Initiates Phase 2a Clinical Trial of COVID-19 Vaccine Candidate

  9/29/2020

  CureVac N.V., a clinical-stage biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid, announced that the first participant has been dosed in a Phase 2a clinical trial of its COVID-19 vaccine candidate, CVnCoV.

• 

  Biopharma Update on the Novel Coronavirus: August 21

  8/21/2020

  Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for August 21, 2020.
• 

  Biopharma Update on the Novel Coronavirus: August 17

  8/17/2020

  Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for August 17, 2020.

• CureVac Announces Pricing of Initial Public Offering

  8/14/2020

  CureVac B.V. announced the pricing of its initial public offering of 13,333,333 common shares at an initial public offering price of $16.00 per common share, for total gross proceeds of approximately $213.3 million.